Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (Universidad de los Andes)
- Development stage
- Unknown
- Lead developer
- Universidad de los Andes
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord mesenchymal stem cells (ucMSCs) developed by the Universidad de los Andes and its spin-off company Cells for Cells (C4C) is an investigational allogeneic cell therapy for the treatment of heart failure and dilated cardiomyopathy. The therapy consists of mesenchymal stem cells isolated from human umbilical cord tissue, which are administered via intravenous infusion. These cells are hypothesized to exert therapeutic effects through paracrine mechanisms, secreting immunomodulatory, anti-inflammatory, and pro-angiogenic factors that promote cardiac tissue repair, reduce myocardial fibrosis, and improve ventricular function. The therapy was evaluated in the Phase 1/2 RIMECARD clinical trial, which demonstrated that intravenous infusion of ucMSCs was safe and resulted in significant improvements in left ventricular ejection fraction (LVEF) and functional capacity in patients with stable heart failure and reduced ejection fraction (HFrEF).
- Other names
- Umbilical cord-derived mesenchymal stem cellsuc-MSCs
Beyond the preview
Go deeper on Umbilical cord mesenchymal stem cells (Universidad de los Andes).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical cord mesenchymal stem cells (Universidad de los Andes).